Table 5.
Effects of resveratrol formulations on cell viability (a) and ROS levels (b) in AMD patient # 3.
| (a) AMD PATIENT #3_Resveratrol Effects on Cell Viability. | |||
| Cell Viability | Percent Increase/p-Value |
Untreated
Mean ± SEM |
Resveratrol Brands
Mean ± SEM |
| AMD UN vs. AMD B1-treated | 31% 0.0003 |
1 ± 0.04315 | 1.310 ± 0.01742 |
| AMD UN vs. AMD B2-treated | 48% 0.0014 |
1 ± 0.04315 | 1.480 ± 0.02474 |
| AMD UN vs. AMD B3-treated | 57.9% 0.0014 |
1 ± 0.04315 | 1.579 ± 0.1443 |
| AMD UN vs. AMD B4-treated | 53.4% 0.0014 |
1 ± 0.04315 | 1.534 ± 0.02238 |
| AMD UN vs. AMD B5-treated | 42.7% 0.0014 |
1 ± 0.04315 | 1.427 ± 0.01969 |
| AMD UN vs. AMD B6-treated | 16.9% 0.0175 |
1 ± 0.04315 | 1.169 ± 0.01962 |
| (b) AMD PATIENT #3_Resveratrol Effects on ROS Levels. | |||
| Ros Levels | Percent Decrease/p-Value |
Untreated
Mean ± SEM |
Resveratrol Brands
Mean ± SEM |
| AMD UN vs. AMD B1-treated | 66.68% 0.0014 |
1 ± 0.02114 | 0.3332 ± 0.01312 |
| AMD UN vs. AMD B2-treated | 49.79% 0.0014 |
1 ± 0.02114 | 0.5021 ± 0.008318 |
| AMD UN vs. AMD B3-treated | 54.96% 0.0014 |
1 ± 0.02114 | 0.4504 ± 0.01886 |
| AMD UN vs. AMD B4-treated | 19.68% 0.0021 |
1 ± 0.02114 | 0.8032 ± 0.03226 |
| AMD UN vs. AMD B5-treated | 4.17% 0.5074 |
1 ± 0.02114 | 0.9583 ± 0.04245 |
| AMD UN vs. AMD B6-treated | 17.2% 0.0294 |
1 ± 0.02114 | 0.8280 ± 0.04493 |